Interaction of titanium, zirconia and lithium disilicate with peri-implant soft tissue: study protocol for a randomized controlled trial by unknown
STUDY PROTOCOL Open Access
Interaction of titanium, zirconia and lithium
disilicate with peri-implant soft tissue: study
protocol for a randomized controlled trial
Katharina Kuhn1*†, Heike Rudolph1†, Michael Graf1, Matthias Moldan1, Shaoxia Zhou2, Martin Udart3,
Andrea Böhmler3 and Ralph G. Luthardt1
Abstract
Background: Against the background of increasing use of dental implants, and thus an increasing prevalence of
implant-associated complications, a deeper understanding of the biomolecular mechanisms in the peri-implant
tissue is needed. Peri-implant soft tissue is in direct contact with transmucosal dental implant abutments. The aim
of this trial is to distinguish the biomolecular and histological interactions of various dental abutment materials with
peri-implant soft tissue.
Methods/Design: The study is designed as a prospective, randomized, investigator-initiated clinical pilot trial
with blinded assessment. We will ultimately include 24 eligible patients who opt for implant treatment to replace
a single missing posterior tooth. Three months after implantation (submerged procedure), the study begins with
the second-stage surgery. Each of the 24 patients will be given three different transmucosal abutments (zirconia,
lithium disilicate, titanium) consecutively. The sequence in which the three materials are used is randomized.
Peri-implant crevicular fluid is sampled weekly around the respective abutment for biomolecular analyses. After
one month of wearing time, the stamping press from the second-stage surgery is used to gain a narrow gingival
ring biopsy around the abutment for immunohistochemical analyses. The next abutment is then inserted. The
same procedure is used for all three abutments. After sampling is completed, the patients will receive a definitive
crown. The primary outcome measure of the trial is biomolecular detection of specific markers in the peri-implant
crevicular fluid: matrix metalloproteinase 8, interleukin- 1β, polymorphonuclear elastase, and myeloid-related protein
MRP8/14 (calprotectin). Secondary outcome measures include immunohistochemical analyses and clinical parameters.
Discussion: The study design will allow us to perform correlation analyses between the clinical indices with
biomarkers’ expression in the interface of the transmucosal abutments and the peri-implant soft tissue. A deeper
understanding of the three abutment materials’ interactions with peri-implant soft tissue will help us understand the
formation mechanisms of implant-associated complications and then develop prevention strategies.
Trial registration: The trial is registered at the German Clinical Trial Register and the International Clinical Trials Registry
Platform by the WHO under DRKS00006555 (Registered on 27 October 2014).
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Background
The prevalence of biological implant-associated complica-
tions rises with the increasing use of dental implants. A
common biological complication is peri-implant mucositis
[1, 2], with a prevalence of 50 % of all dental implant sites
[3]. Biological implant-associated complications usually
begin in the peri-implant soft tissue. Both connective tis-
sue and epithelium of the peri-implant soft tissue are in
direct contact with transmucosal implant abutments.
Thus, the interaction between the respective abutment
materials with the peri-implant soft tissue may favor,
counteract, or not influence at all the development of
peri-implant mucositis or of unfavorable mucosal struc-
tures such as an apical shift of the barrier epithelium
[4, 5]. The particular interaction between abutment
materials and soft tissue is likely to be affected by the
abutments’ properties, such as bacterial adhesion [6–8],
surface condition [9–12] (e.g., free surface energy, rough-
ness), and soft tissue integration ability [4, 5]. There is
only low-level evidence available on the interaction be-
tween different abutment materials with peri-implant tis-
sues [13, 14]. It has been suggested in histological studies
that the abutment materials may have an influence on the
stability of peri-implant tissues [4, 5, 15], although clinical
studies that compared titanium to aluminum oxide abut-
ments [16, 17] and titanium to gold-alloy abutments [18]
found no significant differences in the clinical parameters.
Titanium and zirconia are well-established as abutment
materials. Lithium disilicate ceramic has recently been in-
troduced as abutment material [19, 20]. Accordingly, there
is a lack of studies on lithium disilicate compared with ti-
tanium and zirconia as dental implant abutment material.
The abutment’s interaction with peri-implant soft tis-
sue can be analyzed by quantifying possible inflamma-
tion processes. The use of biomolecular analysis of the
peri-implant crevicular fluid (PICF) has been established
[21, 22]. For the PICF marker analyses the biomarkers
matrix metalloproteinase 8 (MMP-8), interleukin-1β
(IL-1ß) and polymorphonuclear elastase (PMN-elas-
tase) proved to be reliable indicators of peri-implant
inflammation [22–28]. They also play important roles
in oral wound healing [29–32]. The biomarker myeloid-
related protein MRP8/14 (calprotectin) has been used only
rarely in PICF marker evaluations [33]. Its correlation with
periodontitis has been proven by means of gingival crevic-
ular fluid analyses [34–37]. Its release from monocytes is
induced by IL-1ß [38].
Only one recently published study [39] compared the
interaction of two abutment materials (titanium versus
zirconia) with peri-implant tissue by means of PICF marker
analyses. No such investigation is available on the biomo-
lecular interaction of lithium disilicate ceramic. Overall, lit-
tle evidence is available on the biomolecular interactions
between different abutment materials and peri-implant soft
tissue. The aim of this study is to analyze the interactions
at the interface of peri-implant soft tissue and three dental
abutment materials (zirconia, lithium disilicate, titanium).
The hypothesis is that this interface differs biomolecu-
larly and immunohistochemically depending on the
specific abutment material used.
Methods/Design
The study protocol is reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT) statement
[40]. The study was designed in accordance with the follow-
ing guidelines:
 World’s Medical Association’s Declaration of Helsinki
 Clinical investigation of medical devices for human
subjects – Good Clinical Practice (ISO 14155:2011)
 Guidelines of Good Clinical Practice (2001/20/EC)
The Ethics Commission of Ulm University approved the
study design on 30 July 2013 (processing number 68/13).
Trial design
This clinical trial was designed as a prospective, random-
ized investigator-initiated pilot trial to be conducted in
one center. In all, 24 patients are intended to participate
in the study after giving informed consent. The study de-
sign was reevaluated after the first three patients had
passed the endpoint of the biomolecular and histological
sampling. Since the first three patients required no adjust-
ments post-treatment, it is feasible that for the treatment
of the remaining 21 patients no further adjustments will
be required.
Participants
Participants will be 24 patients with a single missing tooth
in the posterior area (premolar or molar) with both adja-
cent teeth in situ and who choose to undergo implant re-
placement. Patients will be included in the study provided
they:
 Are between 18 and 75 years of age
 Have an edentulous space at least 7 mm in width
 Have primary implantation or implantation after
two-stage or one-stage augmentation (sinus lift or
minor lateral augmentation)
 Have gingiva ≥ 3 mm in height
 Are in need of prosthetic treatment
 Are legally competent
Patients will be excluded from the study if:
 Extensive lateral one-stage augmentation is required
(two-stage augmentation with bone block and
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one-stage sinus lift or minor lateral augmentation
is possible)
 They are smokers
 Implant insertion using an implant template before
the beginning of the study is not possible
 The edentulous space < 7 mm in width
(conservation of papilla)
 The gingiva < 3 mm in height at the lowest point
 There is no consent given for study participation
 A chronic disease is present
 They are pregnant
 There is evidence of alcohol or drug abuse
Settings and locations where the data will be collected
The study is taking place at the Department of Pros-
thetic Dentistry, Center of Dentistry, Ulm University.
Screening began in August 2013. So far, the first eight
patients have received a single-tooth implant. Five of
the eight have already finished the study. All patients
gave informed consent. The biomolecular analyses will
take place in the Department of Clinical Chemistry,
Ulm University. The immunohistochemical analyses
will be carried out at the Institut für Lasertechnologien
in der Medizin und Messtechnik, Ulm University.
Completion of the study (last patient out) is planned
for mid-2016.
Interventions
All 24 patients will have received the three abutments con-
secutively, each for a 1-month wearing period. The abut-
ments are as follows: zirconia ceramic (Z) (Zenostar MO;
Wieland Dental GmbH, Pforzheim, Germany; lot S13270);
lithium disilicate ceramic (L) (IPS e.max Press; Ivoclar
Vivadent, Schaan, Liechtenstein; lot S44695); titanium
(T) (Zenotec Ti; Wieland Dental GmbH, Pforzheim,
Germany; lot 20130305 4012). The sequence of the three
materials is randomly assigned. The abutments are manu-
factured by luting hollow Z-, L-, or T-cylinders on Vario-
bases™ (Straumann, Basel, Switzerland; lot: HE661/HK699)
by means of Multilink® Hybrid Abutment cement (Ivoclar
Vivadent, Schaan, Liechtenstein; lot: T10017). The abut-
ments’ surface roughness is adjusted by polishing them to
ensure conformity. The results are checked by Ra measure-
ments of each abutment (Ra < 0.1 μm).
The examinations and specific data collection are shown
in Table 1. Screening is performed before implantation to
check the inclusion/exclusion criteria. Implantation is per-
formed according to the standardized implantation pro-
cedure in the Department of Prosthetic Dentistry making
use of the Straumann®-guided surgery implantation system
(Straumann, Basel, Switzerland) in combination with an
implantation template after three-dimensional implant
planning (CoDiagnostix; Dental Wings GmbH, Chem-
nitz, Germany). Bone-level Straumann implants (SLAc-
tive, RC) are submerged.
Informed consent is given during the healing period
(90 ± 14 days). Inclusion in the study and randomization
takes place prior to the second-stage surgery (baseline). For
the second-stage surgery, a stamping press is used, with a
punch biopsy serving as a histological control specimen.
The first abutment (Z, L, or T) is inserted (20 Ncm) ac-
cording to the randomization process. The occlusal screw
hole is provisionally closed by means of a piece of dental
foam and Luxatemp Inlay (DMG, Hamburg, Germany),
which is light-cured. These materials are not in contact
with the gingiva.
Peri-implant crevicular fluid (PICF) is sampled both
buccally and lingually every week using paper strips
Table 1 Examinations and collected data
Examination type Examination time Collected data
Screening Before implantation; every patient eligible for the
study regardless of his/her participation in the trial
Checking of the inclusion/exclusion criteria
Implantation Before inclusion in clinical trial
Pretreatment examination Before randomization Clinical control of implant site; informed consent
Baseline: second-stage surgery and
insertion of first abutment
90 ± 14 days after implantation Tissue sampling (control punch biopsy)
Photo documentation
X-ray control
PICF sampling 7, 14, 21, and 28 (±1) days after insertion of the first,





Bleeding on probing (BOP)
Tissue sampling and insertion of second
and third abutments
2–5 days after the last PICF sampling around the first,
second, and third abutment
Tissue sampling (ring biopsy)
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(Periopaper; Oraflow Inc., New York, NY, USA). Before
PICF sampling, supragingival plaque is carefully re-
moved with cotton balls to eliminate the risk of plaque
contamination. Cotton rolls are applied to isolate the
sample from saliva. After air-drying the teeth, the
paper strips are inserted into the sulcus/pocket until
there is mild resistance and then left there for 30 seconds.
Samples with visible blood contamination are discarded. In
addition to weekly PICF sampling, clinical parameters are
recorded for the implant and both adjacent teeth, including
the Plaque Index (PI), Gingival Index (GI), probing depth
(PD) using an electronic pressure-sensitive probe (Flori-
daProbe, Essen, Germany) at four sites (mesiobuccal, disto-
buccal, mesiolingual, distolingual), and bleeding on
probing (BOP). After a 1-month wearing period, the abut-
ment is exchanged for the next one. Before unscrewing the
abutment, the stamping press from the second-stage sur-
gery is used to gain a narrow (0.6 mm) gingival ring bi-
opsy around the abutment for immunohistochemical
analyses (Figs. 1 and 2). The same procedure as de-
scribed above is repeated for the second and third abut-
ments. After completion of the sampling for
biomolecular and immunohistochemical analyses, the
study is completed, and the patient receives a screw-
retained lithium disilicate crown.
The three clinical investigators collecting the data re-
ceived training before the first study visit to guarantee
conformity.
Biomolecular analyses
The paper strips collected for biomolecular analyses are
frozen immediately after sampling (−80 °C) and remain
frozen until assayed. For the analyses, the PICF is released
from the paper strip by means of analysis buffer. The incu-
bation takes place on an orbital shaker on ice, and separ-
ation is performed by centrifugation. The supernatant is
collected into a fresh tube. To exclude erythrocyte contam-
ination, all extracts are examined with the Combur-Test®
strip (Roche Diagnostics GmbH, Mannheim, Germany).
The PICF extracts are analyzed for biomolecular detection
of specific markers: MMP-8, IL-1β, PMN-elastase and
MRP8/14 (calprotectin). MMP-8 is analyzed with the
Fluorokin MAP Multiplex Human MMP Panel (R & D
Systems GmbH, Wiesbaden, Deutschland) in the Luminex
200 System (Bio-Rad Laboratories Inc., Hercules, CA,
USA). The MMP-8 activity is detected by means of gel-
atine-zymography. IL-1ß is measured by the Bio-Plex Cyto-
kine Assay Kit (Bio-Rad Laboratories Inc., Hercules, CA,
USA) in combination with the Luminex 200 System.
PMN-elastase is measured by means of the Human Elastase
ELISA Kit (HyCult Biotechnology, Uden, Netherlands) and
MRP8/14 is measured with the MRP8/14 ELISA Kit (Bühl-
mann Laboratories AG, Schönenbuch, Switzerland). The
optical density for both kits is measured at 450 nm. The
sensitivities are as follows: MMP-8, 8.9 pg/ml; IL-1β,
0.2 pg/ml; PMN-elastase, 0.4 ng/ml; MRP8/14, < 0.4 μg/ml.
Immunohistochemical analyses
Each of the four gingival biopsies per patient (one control
punch biopsy and three ring biopsies around the abutment
materials) (Fig. 2d) are equally divided into quarters for the
immunohistochemical analyses. The biopsy specimens are
fixed immediately in 4 % neutral buffered formalin at room
temperature and left there for 24 hours before embedding
them in paraffin. Three micrometer thick sections are pre-
pared prior to deparaffinization. A citrate buffer (pH 6.1;
Target Retrieval Solution, Dako, Carpinteria, CA, USA) is
applied. A steamer is used for antigen retrieval (20 minutes)
and the slides cool off for 20 minutes. A serum blocking
solution (Histostain-Plus Bulk Kit, Invitrogen®, Camarillo,
CA, USA; 20 minutes) is applied. The specimens are incu-
bated with the primary antibodies Anti-Neutrophil Elastase
(over night; 4 °C; 1:500), Anti-MMP 8 (over night; room
temperature; 4 μg/ml), Anti-IL 1β (over night; room
temperature; 1:12.5) or Anti-MRP8 antibody (over
night; 4 °C; 1:750), respectively (Abcam®, Cambridge,
Great Britain), targeting the same molecules which are an-
alyzed by the biomolecular analysis. Hydrogen peroxide
0.3 % is applied to block endogenous peroxidase (10 mi-
nutes). A secondary biotinylated antibody (Histostain-
Plus Bulk Kit, Invitrogen®, Camarillo, CA, USA) is used
(10 minutes). Streptavidin conjugated with horseradish
peroxidase (Histostain-Plus Bulk Kit, Invitrogen®, Camarillo,
CA, USA) is applied (15 minutes). An AEC chromogen
(AEC Single Solution, Invitrogen®, Camarillo, CA, USA) is
applied (15 minutes) for final staining. The specimens are
Fig. 1 Sampling for the immunohistochemical analyses
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then counterstained with hematoxylin and mounted with
Aquatex (Merck, Darmstadt, Germany). Negative controls
are obtained by treating the sections similarly but, instead
of the primary antibodies, Tris-buffered saline (TBS) is
used. The staining is performed in serial sections from each
specimen (e.g., lingual quarter of the control punch
biopsy).
A digital image analysis system, which consists of a
light microscope Axiophot (Carl Zeiss Jena, Oberkochen,
Germany) and a digital color camera ProgRes C12 plus
(Jenoptik, Jena, Germany) connected to a computer
equipped with PeogRes-Software, is used to obtain im-
ages of the microscopic samples (magnification 100× to
400×). Morphometric analyses are performed using the
software ImageJ (National Institutes of Health, Bethesda,
MD, USA) with the plugins Grid and CellCounter as pre-
viously described [41].
Outcomes
The primary outcome measure is the biomolecular detec-
tion of specific markers (MMP-8, IL-1β, PMN-elastase,
MRP8/14) in the PICF samples. Secondary outcome mea-
sures include immunohistochemical analyses and clinical
parameters (PI, GI, PD, BOP).
Sample size
The study is biometrically categorized as a pilot study be-
cause of the sample size of 24 patients. During establish-
ment of the study design, there were no clinical results on
which a biometrical sample size estimation could be based.
The sample size has, therefore, been set at 24 patients. The
weekly PICF sampling both buccally and lingually results
in 24 PICF samples from each patient. Four histological
specimens (one control punch biopsy and three ring biop-
sies) are to be collected from each patient.
Randomization
Randomization is performed with a threefold crossover
design. The sequence of the three abutment materials is
randomly assigned, resulting in six groups (ZLT, ZTL,
LZT, LTZ, TZL, TLZ) with four samples for each. The
study is stratified into the two gender groups.
Randomization concealment is ensured because a clinic
staff member not involved in the clinical trial performs
the allocation according to a randomization list.
Any eligible patient is recorded in a screening list main-
tained by the clinical investigators. Once a patient has given
informed consent, a patient number and randomization are
requested from the staff member performing the allocation
according to the randomization list. The clinical investiga-
tor enters the patient number into the patient list, which
also includes the appointments of each patient. The patient
number and sequence of the abutment materials are trans-
ferred into the Case Report File of the baseline visit (sec-
ond-stage surgery).
Blinding (masking)
Masking is not possible for the dentist or the patient be-
cause of the visually distinguishable abutment materials.
All analyses, however, are to be done masked because of
the different personnel and spatial separation.
Statistical methods
An explorative data analysis will be performed. The data
will be analyzed descriptively by means of absolute and
relative frequency and medians and means, respectively,
as well as measures of dispersion. The analysis of the pri-
mary and secondary outcome measures will be performed
using adequate statistical tests according to the distribu-
tion patterns. Power analyses and sample size estimation
will be done for similar clinical studies in the future.
Discussion
Against the background of a high prevalence of bio-
logical peri-implant complications [3], the mechanisms
of the interface between peri-implant soft tissue and
transmucosal abutments are of interest. The aim of the
present clinical study is to obtain a deeper understanding
of the interaction mechanisms via PICF marker analyses
and immunohistochemical analyses.
To date, only one recently published cross-sectional clin-
ical study [39] has investigated the interaction of abutment
materials (titanium versus zirconia) with peri-implant
Fig. 2 Tissue sampling. a Clinical situation after applying the stamping press around the zirconia abutment. b After removing the gingival ring
biopsy and the zirconia abutment. c After inserting the titanium abutment. d Gingival ring biopsy
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tissue by means of PICF marker analyses. No significant
differences were found between the biomarkers’ quan-
tity (except for leptin). The present study has only the
biomarker IL-1β in common with the other clinical study.
Clinical parameters were not recorded (except for the
presence or absence of plaque) at the time of PICF sam-
pling. The authors recognize the benefits of a prospect-
ive, randomized clinical trial including the collection of
clinical indexes for correlation with biomarker expres-
sion [39]. Our study design met those requirements.
Moreover, we included a third material, lithium disili-
cate ceramic, which is not as well- established as titan-
ium and zirconia for use as abutment material. It has
been shown, however, to be an increasingly relevant ma-
terial for abutments [19, 20]. Titanium serves as “gold
standard.”
PICF marker analyses have been established to detect
peri-implant inflammation [21, 22]. For the PICF marker
analyses, we use three well-established biomarkers (MMP-
8, IL-1ß, PMN-elastase) and MRP8/14. To date, MRP8/14
has been used only rarely in PICF marker evaluations [33].
The combination of well-established biomarkers with a ra-
ther new one allows us to evaluate its suitability for PICF
marker analyses.
The role of plaque formation must be taken into account
in terms of dental materials’ interaction with peri-implant
soft tissue. Plaque is associated with peri-implant mu-
cositis [42, 43] and is correlated with elevated inflam-
matory markers in PICF [28, 44]. In our study, we
clinically determine the PI for correlation analyses with
the number of biomarkers in PICF, which has not been
sufficiently investigated because of the wide range of
biomarkers. The formation of biofilm on dental mate-
rials has been especially well-examined for titanium
and zirconia [6–9, 45]. The results are inconsistent,
however, as zirconia shows less bacterial adhesion and
colonization in some studies [7, 45, 46] and no differ-
ences in others [6, 8]. In the context of plaque forma-
tion, the role of surface roughness also must be discussed.
Excessive surface roughness of dental materials favors bio-
film formation [11, 12] with more complex microbiota
[10]. A threshold for the Ra value of abutment surfaces
has been found (0.2 μm), however, below which no further
significant changes occur in regard to plaque accumula-
tion [9]. The interaction between the three abutment ma-
terials with the peri-implant soft tissue should not be
biased by different surface roughness in the present study.
Therefore, we adjusted the Ra values of all abutments for
uniformity, as indicated in previous studies [8, 45], and
well below the above-mentioned threshold.
Wound healing also influences the results of PICF
marker analyses [47]. This aspect will not bias our study as
the study design guarantees analogue wound healing condi-
tions for all abutment materials. Each abutment is inserted
immediately after a circular gingival biopsy is performed
with a stamping press. Thus, each abutment material is
circularly in contact with open wound edges, and the
1-month PICF sampling takes place during the early
wound healing period for each of the three abutments.
This is a clinically relevant procedure especially for the
“one abutment – one time” concept, where the defini-
tive abutment is inserted directly after implantation
(direct loading) or directly after second-stage surgery
(delayed loading) without removing it again [48–50].
The original biopsy material (punch biopsy from second-
stage surgery) serves as histological control specimen as it
has not been in contact with an abutment material so far.
It will also be stained immunohistochemically to detect the
four biomarkers.
Washout periods between the different abutment ma-
terials may help to exclude an influence of the preceding
abutment material on the tissues. Washout periods may
be performed either by wearing a “neutral” abutment for
a specific time between the tested abutments or by per-
mitting tissues to heal without an abutment and punch
biopsy again before inserting the next abutment. Follow-
ing discussion with biometricians, the additional punch
biopsies and time on top of an already prolonged proced-
ure were deemed ethically unjustifiable. In addition, the
newly formed cells and tissue in direct contact with each
abutment are most likely to be affected and are circularly
removed by the stamping press. Thus, we renounced
washout periods in the trial. However, an influence of
the preceding abutment material on the biomolecular
and immunohistochemical findings of the next abutment
material cannot be fully excluded. To the author’s know-
ledge, there is no study which has tested this aspect yet. If
our biometricians detect clear evidence of previous abut-
ment influence (worst-case scenario) only the first abut-
ment material (n = 8 for each abutment material) shall be
used for analysis.
The study combines biomolecular and immunohisto-
chemical analyses – both aiming to detect the same bio-
markers – and clinical analyses. This design allows a
site-specific correlation analysis between those two tech-
niques for biomarker detection as well as clinical indices
to monitor gingival health.
This study is the first randomized clinical trial to combine
biomolecular, immunohistochemical, and clinical analyses
to determine the environment around transmucosal
abutments during wound healing in humans. Two well-
established abutment materials (titanium and zirconia) are
compared with a more recently introduced abutment ma-
terial (lithium disilicate). A deeper understanding of abut-
ment materials’ interactions with peri-implant soft tissue
will help us comprehend the formation mechanisms of
implant-associated complications and to develop preven-
tion strategies.
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Trial status
The screening and recruiting for the study began in August
2013 and is still ongoing. To date, the first eight patients
have received a single-tooth implant. Five of the eight have
finished the study.
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